The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population

Vaccine

Volumn 20, Issue 31-32, 2002, Pages 3644-3649

  Jacques, P ^a   Moens, G ^a,b   Desombere, I ^c   Dewijngaert, J ^a   Leroux Roels, G ^c   Wettendorff, M ^d   Thoelen, S ^d  

^a EXTERNAL SERVICE FOR PREVENTION AND PROTECTION AT WORK   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Hepatitis B; Immunogenicity; Reactogenicity

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; IMMUNOLOGICAL ADJUVANT; RECOMBINANT VACCINE; VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; BIOSYNTHESIS; BLOOD; CELLULAR IMMUNITY; COMPARATIVE STUDY; FEMALE; HISTOCOMPATIBILITY TEST; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; SINGLE BLIND PROCEDURE;

ADJUVANTS, IMMUNOLOGIC; ADULT; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION SCHEDULE; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; VACCINES, COMBINED; VACCINES, SYNTHETIC;

EID: 0036841343     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00397-3     Document Type: Article

References (20)

1. Kane M.A. Global programme for control of hepatitis B infection. Vaccine. 13:1995;S47-49.
2. Adkins J.C., Wagstaff A.J. Recombinant hepatitis B vaccine: a review of its immunogenicity and protective efficacy against hepatitis B. Biodrugs. 10:1998;137-158.
3. Safary A., André F. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine. 18:1999;57-67. (and references therein).
4. Poovorawan Y., Sanpavat S., Theamboonlers A., Safary A. Long term follow-up (11-13 years) of high risk neonates vaccinated against hepatitis B. Antiviral Therapy. 5:2000;24.
5. Vellinga A., Van Damme P., Weyler J.J., Vranckx R., Meheus A. Hepatitis B vaccination in mentally retarded: effectiveness after 11 years. Vaccine. 17:1999;602-606.
6. WHO Anonymous. Hepatitis B: making global progress. WHO website: http://www.who.int/gpv-dvacc/diseases/hepatitis_b.htm.
7. Coates T., Wilson R., Patrick G., André F., Watson V. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clinical Ther. 23:2001;392-403.
8. Zuckerman J.N. Non-response to hepatitis B vaccines and the kinetics of anti-HBs production. J. Med. Virol. 50:1996;283-299.
9. Desombere I., Willems A., Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA genes are involved. Tissue Antigens. 51:1998;593-604.
10. Thoelen S., Van Damme P., Mathei C.et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine. 16:1998;708-714.
11. Ambrosch F., Wiedermann G., Kundi M.et al. A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine. 18:2000;2095-2101.
12. Buyse I., Decorte R., Baens M.et al. Rapid DNA typing of class II HLA antigens using the polymerase chain reaction and reverse dot blot hybridisation. Tissue Antigens. 41:1993;1-14.
13. Leroux-Roels G., Van Hecke E., Michielsen W., Voet P., Hauser P., Pètre J. Correlation between in vivo humoral and in vitro cellular immune responses following immunisation with hepatitis B surface antigen (HBsAg) vaccines. Vaccine. 12:1994;811-818.
14. Hadler S.C., Francis D.P., Mayjnard J.E., Thompson S.E., Judson F.N., Echenberg D.F.et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. New Engl. J. Med. 315(4):1986;209-214.
15. Clemens R., Sänger R., Kruppenbacher J. Booster immunisation of low-and non-responders after a standard three dose hepatitis B vaccine schedule - results of a post-marketing surveillance. Vaccine. 15:1997;349-352.
16. Anon. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunisation Practices Advisory Committee (ACIP). MMWR 1991;40(RR-13):1-19.
17. Goldwater P. Randomised, comparative trial of 20 μg vs. 40 μg Engerix-B vaccine in hepatitis B vaccine non-responders. Vaccine. 15:1997;353-356.
18. Desombere I., Leroux-Roels G., Van der Wielen M., Van Damme P., Collard F., Thoelen S. HLA DQ2 positive subjects vaccinated with a hepatitis B vaccine with a novel adjuvant (HBsAg/AS04). Antiviral Therapy. 5:2000;B48.
19. McDermott A.B., Zuckerman J.N., Sabin C.A., Marsch S.G.E., Madriga J.A. Contribution of human leucocyte antigens to the antigen response to hepatitis B vaccination. Tissue Antigen. 50:1997;8-14.
20. Banatvala J., Van Damme P., Oehen S. Lifelong protection against hepatitis B - the role of vaccine immunogenicity in immune memory. Vaccine. 19:2001;877-885.